<div class="docx-content">
<h1 class="text-2xl font-bold mt-8 mb-4">Epididymo-OrchitisBASHH 2020 guidance </h1><p><strong>1  Scope &amp; Audience</strong></p><ul><li>Management of epididymo-orchitis (EO) in people ≥ 16 y presenting to UK level-3 STI services; principles are widely transferable.</li><li>Developed with AGREE II framework, MEDLINE/Cochrane review (2009-2017) and public consultation; next update due ≤ 2025.  </li></ul><p><strong>2  What’s NEW in the 2020 guideline</strong></p><ul><li>Empirical therapy: ceftriaxone 1 g IM + doxycycline becomes first-line for presumed sexually-acquired EO (higher ceftriaxone dose mirrors 2018 gonorrhoea guideline).</li><li>Enteric-risk regimens clarified: fluoroquinolone or amoxicillin/clavulanate options.</li><li>BCG-related TB EO added; brucella serology advised for endemic-area cases.</li><li>Imaging: colour duplex US cannot reliably exclude torsion; if clinical doubt → urgent exploration.</li><li>Patient leaflet &amp; a simplified clinical care pathway introduced.  </li></ul><p><strong>3  Aetiology &amp; Risk Stratification</strong></p><table><thead><tr><th><p><strong>Group</strong></p></th><th><p><strong>Likely pathogens</strong></p></th><th><p><strong>Notable risk factors</strong></p></th><th><p><strong>Key points</strong></p></th></tr></thead><tbody><tr><td><p>&lt; 35 y</p></td><td><p>C. trachomatis, N. gonorrhoeae</p></td><td><p>new/ multiple partners, MSM</p></td><td><p>treat as STI-related.</p></td></tr><tr><td><p>≥ 35 y</p></td><td><p>Gram-negatives (e.g. coliforms)</p></td><td><p>UTI, catheter/instrumentation, prostate biopsy</p></td><td><p>investigate urinary tract.</p></td></tr><tr><td><p>Insertive anal sex (any age)</p></td><td><p>STI-associated enteric organisms</p></td><td><p>–</p></td><td><p>cover both STI &amp; enteric.</p></td></tr><tr><td><p>Special causes</p></td><td><p>TB (incl. post-BCG), brucella, M. genitalium, Ureaplasma, mumps, Behçet, H-S purpura, amiodarone, vasculitides, schistosomiasis, PVL-S. aureus.</p></td><td><p>Travel, immunodef., drug history.</p></td><td><p>think widely if atypical / poor response.</p></td></tr></tbody></table><p><strong>4  Clinical Presentation</strong></p><ul><li>Symptoms: acute unilateral scrotal pain, swelling, erythema ± UTI/urethritis features.</li><li>Torsion is the must-exclude emergency (sudden severe pain, high-riding testis, N+V).</li><li>Disease-specific clues:</li></ul><p>TB – subacute painless mass ± sinus; mumps – parotitis 7-10 d earlier; brucellosis – fever, night sweats.</p><ul><li>Complications: reactive hydrocoele, abscess, testicular infarction, infertility (esp. bilateral mumps).  </li><li>Abnormal urinary tracts (e.g. anorectal malformations) and neurogenic bladder dramatically raise risk of Gram-negative EO – always arrange urological imaging.</li></ul><p><strong>5  Investigations (FRCPath favourite!)</strong></p><p>Bedside / clinic</p><ul><li>Urethral Gram stain: ≥ 5 PMNL/HPF = urethritis; intracellular GN diplococci = gonorrhoea.</li><li>FPU dipstick: leucocyte esterase ± nitrite supports UTI/urethritis.</li></ul><p>Laboratory</p><ul><li>FPU/urethral NAAT for C. trachomatis &amp; N. gonorrhoeae; consider M. genitalium.</li><li>MSU culture for uropathogens. Full STI screen incl. BBVs.</li><li>Brucella serology (IgM/IgG) if from endemic region; consider AAFB culture/acid-fast bacilli tests, mumps serology/PCR when clinically indicated.</li></ul><p>Imaging / further tests</p><ul><li>Colour duplex US when diagnosis unclear or to assess complications, not to rule out torsion in acute setting.</li><li>Urgent surgical exploration if torsion cannot be excluded clinically.</li><li>Urology evaluation (renal US/CT, cystoscopy) in confirmed UTI-related EO.</li><li>Brucella serology, TB work-up as indicated.  </li></ul><p><strong>6  Management</strong></p><p>General measures</p><ul><li>Advise analgesia (NSAID), rest, scrotal support; abstain from sex until completion of therapy &amp; partner management.</li><li>Provide patient information leaflet.</li></ul><p>Empirical antibiotic regimens</p><table><thead><tr><th><p><strong>Scenario (start treatment at first visit)</strong></p></th><th><p><strong>Regimen &amp; duration</strong></p></th><th><p><strong>Grade</strong></p></th></tr></thead><tbody><tr><td><p>Presumed STI-related</p></td><td><p>Ceftriaxone 1 g IM single + doxycycline 100 mg PO bd 10-14 d</p></td><td><p>1A</p></td></tr><tr><td><p>Confirmed chlamydia / non-GC (gonorrhoea ruled out)</p></td><td><p>Doxy 100 mg bd 10-14 d or ofloxacin 200 mg bd 14 d</p></td><td><p>1A</p></td></tr><tr><td><p>Likely enteric / urinary cause</p></td><td><p>Ofloxacin 200 mg bd 14 d or levofloxacin 500 mg od 10 d</p></td><td><p>1A / 2C</p></td></tr><tr><td><p>Mixed STI + enteric risk (insertive anal sex)</p></td><td><p>Ceftriaxone 1 g IM single + ofloxacin 200 mg bd 10 d</p></td><td><p>1A</p></td></tr><tr><td><p>Quinolone-contraindicated</p></td><td><p>Amoxicillin/clavulanate 625 mg tds 10 d</p></td><td><p>1A</p></td></tr><tr><td><p>Severe / septic</p></td><td><p>Admit; IV cefuroxime 1.5 g tds ± gentamicin 3-5 d then oral step-down</p></td><td><p>–</p></td></tr><tr><td><p>Cephalosporin / tetracycline allergy</p></td><td><p>Ofloxacin 200 mg bd 14 d or ciprofloxacin 500 mg bd 7-10 d once </p></td><td><p>1A</p></td></tr><tr><td><p>M. genitalium positive</p></td><td><p>Add moxifloxacin 400 mg od 14 d</p></td><td><p>1D</p></td></tr></tbody></table><ul><li>Discuss EMA warnings: tendonitis / neurotoxicity with quinolones; stop drug at first sign.</li><li>Steroids have no proven benefit in acute EO.  </li></ul><p>Partner notification &amp; treatment</p><ul><li>Look-back: ≥ 4 w for chlamydia; ≥ 2 w (or last partner) for gonorrhoea.</li><li>Partners: full STI testing and empiric cover for GC/CT if index positive.  </li></ul><p>Follow-up</p><ul><li>Review culture/NAAT results at 48-72 h; adjust therapy.</li><li>Clinical review at 2 w (telephone ok if improving).</li><li>No improvement by day 3 → reassess diagnosis, image for abscess/infarction.</li><li>Swelling usually resolves &gt; 80 % by 3 mo; persistent cases need ultrasound or surgical opinion; UTI-linked EO warrants urology referral.</li><li>Test-of-cure for gonorrhoea: culture ≥ 72 h post-therapy or NAAT 1-2 w after.  </li></ul><p><strong>7  Exam-Focused Pearls</strong></p><ul><li>Always exclude torsion clinically before imaging; write “urgent scrotal exploration if doubt”.</li><li>High-dose ceftriaxone (1 g) aligns with rising MICs in GC.</li><li>Recognise non-infective mimics (Behçet, H-S purpura, amiodarone) – histology questions may appear.</li><li>BCG-induced TB EO &amp; brucella are classical viva differentials (think travel, intravesical therapy).</li><li>Document auditable outcomes: correct investigations ≥ 90 %, guideline antibiotic ≥ 97 %.</li><li>Infertility risk is mainly with bilateral mumps orchitis (testicular atrophy 30-50 %, subfertility 13 %).  </li></ul><p>Use this checklist in OSPE/viva:</p><ol><li>Assess acute scrotum → rule out torsion → start empiric antibiotics immediately.</li><li>Send FPU NAAT ± MSU culture; full STI screen.</li><li>Risk-stratify (STI vs enteric vs mixed); choose correct regimen + safety-net on quinolone risks.</li><li>Advise analgesia, scrotal support, abstinence, partner testing.</li><li>Arrange 48-72 h review; TOR for GC; urology referral if uropathogen or poor response.</li></ol><p>Good luck with your revision!</p>
</div>